We are almost there ...
PharmEasy is staring at hard times
The online drugs and medical services startup made some costly acquisitions in a bid to pull off an IPO at a high valuation. That plan may be coming unstuck.
21 July, 2022•5 min
0
21 July, 2022•5 min
0
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
Limited time offer $125 $99 for 1 year
SUBSCRIBE
Already have an account? Sign In
More in Business
You may also like
Internet
Why is Swiggy catching flak for its latest quick-delivery promise?
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
Internet
Can Naveen Tahilyani fix Tata Digital’s rot?
The flop show of the super app Tata Neu isn’t the biggest problem for Tata Sons chairman N Chandrasekaran. The new CEO he has now picked has more fundamental issues to fix.
Internet
Can $200 million really save Byju’s?
The announcement of a rights issue seems to be little more than a last-ditch attempt to get existing investors to put in money and help clear urgent current liabilities that could land the founders in prison.
